Connecting via Winsock to STN

Welcome to STN International! Enter x:x

* * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:44:17 ON 19 MAR 2009

=> file reg

=>
Uploading C:\Program Files\Stnexp\Queries\10576853.str



chain nodes :
17 18 19 20 21 22 23 24
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
chain bonds :
4-24 7-20 8-19 10-17 11-17 17-18 20-21 20-22 22-23
ring bonds :
1-2 1-6 1-7 2-3 2-10 3-4 4-5 5-6 7-8 8-9 9-10 11-12 11-16 12-13 13-14
14-15 15-16
exact/norm bonds :
1-7 2-10 7-8 7-20 8-9 9-10 17-18
exact bonds :
4-24 8-19 10-17 11-17 22-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16 20-21
20-22

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 14:44:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 825 TO ITERATE

100.0% PROCESSED 825 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L2 0 SEA SSS FUL L1

```
=> s l1 sam
SAMPLE SEARCH INITIATED 14:45:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       33 TO ITERATE

100.0% PROCESSED       33 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:           316 TO     1004
PROJECTED ANSWERS:                0 TO        0

L3            0 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\222.str
```



```
chain nodes :
17  18  19  20  21  22
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16
chain bonds :
7-20  8-19  10-17  11-17  17-18  20-21  20-22
ring bonds :
1-2  1-6  1-7  2-3  2-10  3-4  4-5  5-6  7-8  8-9  9-10  11-12  11-16  12-13  13-14
 14-15  15-16
exact/norm bonds :
1-7  2-10  7-8  7-20  8-9  9-10  17-18  20-21  20-22
exact bonds :
8-19  10-17  11-17
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  11-12  11-16  12-13  13-14  14-15  15-16
```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l4 sam
SAMPLE SEARCH INITIATED 14:45:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 24 TO ITERATE

100.0% PROCESSED 24 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

```
PROJECTED ITERATIONS:          187 TO      773
PROJECTED ANSWERS:               6 TO      266

L5            6 SEA SSS SAM L4

=> s l4 full
FULL SEARCH INITIATED 14:46:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      321 TO ITERATE

100.0% PROCESSED      321 ITERATIONS                              35 ANSWERS
SEARCH TIME: 00.00.01

L6           35 SEA SSS FUL L4

=> file ca
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL

=> s l6
L7            4 L6

=> d ibib abs fhitstr 1-4

L7   ANSWER 1 OF 4  CA  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        147:392438  CA
TITLE:                   Methods of treatment with CETP inhibitors
INVENTOR(S):             Ruggeri, Roger Benjamin
PATENT ASSIGNEE(S):      Pfizer Products Inc., USA
SOURCE:                  PCT Int. Appl., 58pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
     WO 2007107843        A1    20070927    WO 2007-IB673           20070312
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
            KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN,
            MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
            RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
            GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM
     JP 2007254466        A     20071004    JP 2007-71833           20070320
PRIORITY APPLN. INFO.:                      US 2006-785188P     P   20060322
                                            US 2006-806841P     P   20060710
OTHER SOURCE(S):         MARPAT 147:392438
AB   This invention relates to cholesterol ester transfer protein (CETP)
     inhibitors, pharmaceutical compns. containing such inhibitors, and the use of
     such inhibitors to treat certain disease/conditions optionally in
     combination with certain therapeutic agents, e.g., HMG CoA reductase
```

inhibitors. Tablets contained active ingredient 0.25-100, microcryst. cellulose 200-650, fumed silica 10-650, and stearic acid 5-15 mg/tablet.

IT 880545-74-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of treatment with CETP inhibitors)

RN 880545-74-4 CA

CN 1(2H)-Quinolinecarboxylic acid, 4-[(S)-amino[3,5-bis(trifluoromethyl)phenyl]methyl]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, 1-methylethyl ester, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 4 CA COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 145:195730 CA
TITLE: Drying of drug-containing particles
INVENTOR(S): Ray, Roderick Jack; Newbold, David Dixon; Beyerinck, Ronald Arthur; Dobry, Daniel Elmont; Grove, Kevin Douglas
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006079921	A2	20060803	WO 2006-IB186	20060116
WO 2006079921	A3	20061026		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,

SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

CA 2594694	A1	20060803	CA 2006-2594694		20060116
EP 1855652	A2	20071121	EP 2006-700863		20060116
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
JP 2006206591	A	20060810	JP 2006-18927		20060127
US 20080213375	A1	20080904	US 2007-814592		20070906
PRIORITY APPLN. INFO.:			US 2005-648229P	P	20050128
			WO 2006-IB186	W	20060116

AB A secondary drying process is disclosed for removing residual solvent from drug-containing particles that have been formed by solvent-based processes, the secondary drying process utilizing a combination of vacuum, agitation, and a stripping gas. A solid amorphous dispersion was formed comprising torcetrapib, hydroxypropyl Me cellulose acetate succinate in acetone.

IT 880545-74-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drying of drug-containing particles)

RN 880545-74-4 CA

CN 1(2H)-Quinolinecarboxylic acid, 4-[(S)-amino[3,5-bis(trifluoromethyl)phenyl]methyl]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, 1-methylethyl ester, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 4 CA COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 144:331281 CA
TITLE: Quinoline compounds and their preparation, pharmaceutical compositions and their use as CETP inhibitors for treatment of atherosclerosis and cardiovascular diseases

INVENTOR(S): Didiuk, Mary Theresa; Kelley, Ryan Michael; Perry, David Austen; Ruggeri, Roger Benjamin
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006033004	A1	20060330	WO 2005-IB2890	20050912
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
NL 1030012	A1	20060327	NL 2005-1030012	20050922
NL 1030012	C2	20061121		
US 20070149567	A1	20070628	US 2006-576853	20060420
PRIORITY APPLN. INFO.:			US 2004-612863P P	20040923
			WO 2005-IB2890 W	20050912

GI



I

AB Quinoline compds., pharmaceutical compns. containing such compds. and the use of such compds. to elevate certain plasma lipid levels, including high d. lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans. Example compound I was prepared by reduction of (R)-2-ethyl-4-oxo-6-trifluoromethyl-3,4-

dihydro-2H-quinoline-1-carboxylic acid iso-Pr ester and the resulting underwent chlorination reaction to give (R)-2-ethyl-4-chloro-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid iso-Pr ester, which reacted with benzhydrylidene-[3,5-bis(trifluoromethyl)benzyl]amine; the resulting 4-[(benzhydrylideneamino)-3,5-bis(trifluoromethyl)benzyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid iso-Pr ester underwent hydrolysis to give example compound I. All the invention compds. were evaluated for their in vitro and in vivo CETP activity. From the CETP assay, it was determined that the invention compds. have the ability to elevate certain plasma levels, e.g., HDL cholesterol, and lowering certain plasma levels, e.g., LDL cholesterol and triglycerides.

IT 880545-74-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinoline compds. and their use as CETP inhibitors for treatment of atherosclerosis and cardiovascular diseases)

RN 880545-74-4 CA

CN 1(2H)-Quinolinecarboxylic acid, 4-[(S)-amino[3,5-bis(trifluoromethyl)phenyl]methyl]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, 1-methylethyl ester, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 4 CA COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 141:314351 CA

TITLE: Preparation of 1,2,3,4-substituted 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity

INVENTOR(S): Chang, George; Didiuk, Mary Theresa; Finneman, Jari Ilmari; Garigipati, Ravi Shanker; Kelley, Ryan Michael; Perry, David Austen; Ruggeri, Roger Benjamin;

Bechle, Bruce Michael
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 335 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085401	A1	20041007	WO 2004-IB836	20040315
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004224082	A1	20041007	AU 2004-224082	20040315
CA 2520405	A1	20041007	CA 2004-2520405	20040315
EP 1622872	A1	20060208	EP 2004-720668	20040315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008897	A	20060418	BR 2004-8897	20040315
CN 1795177	A	20060628	CN 2004-80014645	20040315
JP 2006521344	T	20060921	JP 2006-506369	20040315
US 20040204450	A1	20041014	US 2004-807838	20040323
NL 1025839	A1	20040930	NL 2004-1025839	20040326
NL 1025839	C2	20060906		
TW 285641	B	20070821	TW 2004-93108314	20040326
IN 2005DN04056	A	20070831	IN 2005-DN4056	20050909
MX 2005010456	A	20060321	MX 2005-10456	20050928
NO 2005004989	A	20051216	NO 2005-4989	20051026
US 20060122224	A1	20060608	US 2005-305874	20051215
PRIORITY APPLN. INFO.:			US 2003-458274P	P 20030328
			US 2004-536217P	P 20040114
			WO 2004-IB836	A 20040315
			US 2004-807838	A1 20040323

OTHER SOURCE(S): MARPAT 141:314351
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = C; J = N or C, wherein when J = C, then the bond between J and X is a single or double bond, if J = N, then the bond between J and X is a single bond; R1 = Y, W-Z or W-Y; Y = (un)substituted, (un)saturated 3-8 membered ring (or bicyclic ring) optionally having 1-4 heteroatoms, or (un)substituted, (un)saturated 1-10 membered straight or branched carbon chain optionally substituted with 1-2 heteroatoms; W =

carbonyl, thiocarbonyl, sulfinyl, or sulfonyl; Z = OY, SY, NHY or NY2; R2 = (un)substituted, (un)saturated 1-6 membered alkyl or heteroalkyl chain; R3 = (un)substituted, (un)saturated alkyl or heteroalkyl chain; R4, R5, R6, and R7 independently = H, bond, nitro, etc.; or adjacent combinations of R4, R5, R6, and R7 may optionally be taken together to form (un)substituted, (un)saturated carbocycle or heterocyclic ring], and pharmaceutical compns. containing such compds. are prepared and disclosed as cholesteryl ester transfer protein (cetp) inhibitors. Thus, e.g., II was prepared by reaction of 3,5-bistrifluoromethylbenzoyl chloride with 4-diazo-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid Et ester (preparation given) in di-Et ether. Methods for bioassaying compds. I are described (no data). The use of I to elevate certain plasma lipid levels, including high d. lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans is further disclosed.

IT 769131-32-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of quinoline and quinoxaline derivs. as cholesteryl ester transfer protein inhibitors)

RN 769131-32-0 CA

CN 1(2H)-Quinolinecarboxylic acid, 4-[(S)-amino[3,5-bis(trifluoromethyl)phenyl]methyl]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, ethyl ester, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file marpat

=> s l4 full

```
FULL SEARCH INITIATED 14:47:39 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -    23702 TO ITERATE

100.0% PROCESSED    23702 ITERATIONS                          1 ANSWERS
SEARCH TIME: 00.00.14

L8            1 SEA SSS FUL L4

=> d ibib abs fqhit


L8   ANSWER 1 OF 1  MARPAT  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        141:314351  MARPAT
TITLE:                   Preparation of 1,2,4-substituted
                         1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and
                         1,2,3,4-tetrahydro-quinoxaline derivatives as cetp
                         inhibitors for the treatment of atherosclerosis and
                         obesity
INVENTOR(S):             Chang, George; Didiuk, Mary Theresa; Finneman, Jari
                         Ilmari; Garigipati, Ravi Shanker; Kelley, Ryan
                         Michael; Perry, David Austen; Ruggeri, Roger Benjamin;
                         Bechle, Bruce Michael
PATENT ASSIGNEE(S):      Pfizer Products Inc., USA
SOURCE:                  PCT Int. Appl., 335 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ----------------  ----  --------      ---------------  --------
     WO 2004085401     A1    20041007      WO 2004-IB836    20040315
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG
     AU 2004224082     A1    20041007      AU 2004-224082   20040315
     CA 2520405        A1    20041007      CA 2004-2520405  20040315
     EP 1622872        A1    20060208      EP 2004-720668   20040315
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     BR 2004008897     A     20060418      BR 2004-8897     20040315
     CN 1795177        A     20060628      CN 2004-80014645 20040315
     JP 2006521344     T     20060921      JP 2006-506369   20040315
     US 20040204450    A1    20041014      US 2004-807838   20040323
     NL 1025839        A1    20040930      NL 2004-1025839  20040326
     NL 1025839        C2    20060906
     TW 285641         B     20070821      TW 2004-93108314 20040326
     IN 2005DN04056    A     20070831      IN 2005-DN4056   20050909
```

	MX 2005010456	A	20060321	MX 2005-10456	20050928
	NO 2005004989	A	20051216	NO 2005-4989	20051026
	US 20060122224	A1	20060608	US 2005-305874	20051215
PRIORITY APPLN. INFO.:				US 2003-458274P	20030328
				US 2004-536217P	20040114
				WO 2004-IB836	20040315
				US 2004-807838	20040323

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = C; J = N or C, wherein when J = C, then the bond between J and X is a single or double bond, if J = N, then the bond between J and X is a single bond; R1 = Y, W-Z or W-Y; Y = (un)substituted, (un)saturated 3-8 membered ring (or bicyclic ring) optionally having 1-4 heteroatoms, or (un)substituted, (un)saturated 1-10 membered straight or branched carbon chain optionally substituted with 1-2 heteroatoms; W = carbonyl, thiocarbonyl, sulfinyl, or sulfonyl; Z = OY, SY, NHY or NY2; R2 = (un)substituted, (un)saturated 1-6 membered alkyl or heteroalkyl chain; R3 = (un)substituted, (un)saturated alkyl or heteroalkyl chain; R4, R5, R6, and R7 independently = H, bond, nitro, etc.; or adjacent combinations of R4, R5, R6, and R7 may optionally be taken together to form (un)substituted, (un)saturated carbocycle or heterocyclic ring], and pharmaceutical compns. containing such compds. are prepared and disclosed as cholesteryl ester transfer protein (cetp) inhibitors. Thus, e.g., II was prepared by reaction of 3,5-bistrifluoromethylbenzoyl chloride with 4-diazo-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid Et ester (preparation given) in di-Et ether. Methods for bioassaying compds. I are described (no data). The use of I to elevate certain plasma lipid levels, including high d. lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans is further disclosed.

MSTR 1



G1 = 11-4 12-9

G2 = CH
G3 = 23 / 32

G5 = 26

G6 = O
G7 = O
G11 = Me
G14 = 47

G16 = Ph (opt. substd. by (1-3) G17)
G18 = 55

G19 = NH2
Patent location: claim 1
Note: and pharmaceutically acceptable salts or prodrugs
Note: substitution is restricted
Note: additional ring formation also claimed

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:44:17 ON 19 MAR 2009)

FILE 'REGISTRY' ENTERED AT 14:44:35 ON 19 MAR 2009
L1 STRUCTURE UPLOADED
L2 0 S L1 FULL
L3 0 S L1 SAM
L4 STRUCTURE UPLOADED

```
L5             6 S L4 SAM
L6            35 S L4 FULL

     FILE 'CA' ENTERED AT 14:46:02 ON 19 MAR 2009
L7             4 S L6

     FILE 'MARPAT' ENTERED AT 14:47:35 ON 19 MAR 2009
L8             1 S L4 FULL

=>

---Logging off of STN---


=>
Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 14:48:39 ON 19 MAR 2009
```